Meltwater delivers the future of media, social and consumer intelligence through its industry-leading AI engine and ChatGPT integration
Meltwater expands on 20 years of robust AI capabilities with integration of OpenAI models and advanced algorithms to deliver insights, moving away from the time and guesswork needed to make sense of billions of pieces of online data.
SAN FRANCISCO, May 22, 2023 (GLOBE NEWSWIRE) -- Meltwater, a global leader in media, social and consumer intelligence, today announces new AI-powered product innovations across multiple solutions that allow customers to surface insights, boost efficiency, and generate content.
New product enhancements powered by Meltwater’s AI engine:
- AI Writing Assistant – Empowering customers to work more efficiently and overcome writer's block, leveraging the latest advancements in generative AI. Powered by OpenAI’s GPT model, this intuitive tool boosts productivity and creativity, providing users with an effortless way to craft highly engaging content, integrated seamlessly into their publishing workflow.
- Discovery AI-Based Insight Assistant – Leveraging advanced artificial intelligence algorithms to automatically surface impactful consumer and market insights. By highlighting changes, shifts, and trends in online conversations that teams may have otherwise missed, the assistant allows them to stay ahead of the curve and make informed business decisions, solving for information overload with automated, actionable insights.
- Video Analysis – Enabling users to capture insights from video content on social platforms through advanced computer vision which identifies logos, celebrities, scenes and objects. This allows customers to gain a more comprehensive understanding of their online brand and tackle everything from crisis management to content ideation.
These innovations are powered by Meltwater’s AI engine, capitalizing on nearly 20 years of investment and the largest, richest, and most global dataset in the industry. Across these AI enhancements, Meltwater customers are already saving time, benefitting from streamlined workflows, and seeing significant value from these new tools:
- The Discovery Insight Assistant is a fascinating feature, both for its ability to identify relevant information and for its accuracy. It simplifies the task of analyzing and identifying drivers of conversations with completeness and relevance. The potential of Discovery is immense, and it’s a major asset for anyone involved in social data. - Jean-Baptiste Mac Luckie, Senior Market & Business Insights Manager, Lacoste
- “Meltwater’s new Insight Assistant and Video Analysis capabilities have tremendous potential for agencies who are tasked with staying on top of multiple brands across a growing number of news and social channels. Our industry is always changing and evolving, and it's a game-changer to be able to save time, have access to deeper, more accurate insights, and be alerted to key shifts in brand mentions – all powered by the latest innovations in AI.” - James Wright, Global CEO, Red Havas, and CEO, Havas Creative Network Australia
Meltwater delivers AI insights at scale drawing from an unprecedented amount of data – with more than 1.3 billion new documents added each day, applying 14 billion AI inferences, with support in over 240 languages. Additionally, Meltwater’s rich experience with LLMs (large language models), the foundation of generative AI models, puts the company in a leadership position to help customers find insights in the sea of external data.
“Meltwater has been investing in AI since day one, and these new generative AI enhancements will bring even more value to our customers. Harnessing the power of online data is no longer limited to teams with advanced technical skills. Our AI-powered tools bring the full value of media intelligence to organizations of all kinds by surfacing more relevant insights and generating content, ultimately saving time, streamlining workflows, and boosting productivity,” says Meltwater CTO Aditya Jami.
In the coming months, the company will release additional generative AI-powered enhancements that will provide value for Meltwater customers in numerous ways – from simplifying complicated Boolean search set-up, to generating concise content summaries and automating tags for news and social content. These features will drastically simplify how to search and organize data, accelerate user productivity, reduce time-to-strategic-insight, and unblock creative barriers for Meltwater’s 27,000+ customers.
Find out more at the upcoming Meltwater Summit in New York on June 21-22. During the Summit's Product Keynote, Meltwater CEO John Box and CTO Aditya Jami will reveal exciting new launches that leverage AI to empower marketers and communication professionals to spend less time wrangling data and more time strategizing and engaging with their audiences.
To learn more and attend the Summit, visit meltwater.com/summit.
For more information contact:
Kelly Costello
pr@meltwater.com
About Meltwater:
Meltwater empowers companies with a suite of solutions that spans media, social, consumer and sales intelligence. By analyzing ~1 billion pieces of content each day and transforming them into vital insights, Meltwater unlocks the competitive edge to drive results. With 27,000 global customers, 50 offices across six continents and 2,300 employees, Meltwater is the industry partner of choice for global brands making an impact. Learn more at meltwater.com.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Grant of Restricted Stock Units and Warrants to Employees in Genmab8.6.2023 23:22:17 CEST | Press release
Company Announcement COPENHAGEN, Denmark; June 8, 2023 –Genmab A/S (Nasdaq:GMAB) announced todaythat the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,688. The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. The exercise price fo
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants8.6.2023 23:19:00 CEST | Press release
FDA Advisory Committee unanimously recommendsnirsevimab as first immunization against RSV disease forall infants Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approvedAcross all clinical trials, a single dose of nirsevimab delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseThe FDA has indicated it will work to expedite its review; Sanofi remains committed to delivering nirsevimab in time for the 2023-2024 RSV season Paris, June 8, 2023. The U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously 21 to 0 that Sanofi and AstraZeneca’s nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The Committee also voted 19 to 2 in support of nirsevimab’s favorable benefit ris
DBV Technologies to Participate in Upcoming EAACI Congress 20238.6.2023 22:30:00 CEST | Press release
Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the current burden of peanut allergy and treatment management strategies for children in the U.K. DBV will also present data from its completed EPITOPE Phase 3 study assessing the efficacy and safety of epicutaneous immunotherapy (EPIT) using Viaskin Peanut™ in toddlers aged 1-3 years with or without concomitant asthma. The toddler age-group represents the age range in which many peanut-allergic children are diagnosed, yet there are currently n
GOGL - Transactions made under the buy-back program8.6.2023 22:30:00 CEST | Press release
Reference is made to the stock announcement on October 4, 2022, where Golden Ocean Group Limited (OSE/NASDAQ: GOGL) announced the commencement of its share buy-back program of maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the company's common shares in a 12-month period from the announcement. Golden Ocean Group Limited (“GOGL” or the “Company”) announces that the Company has during the week ending Friday June 2, 2023, purchased 25,343 of the Company’s own common stocks. 343 of the shares have been bought on the Oslo Stock Exchange at an average price of NOK 80.00 per share and 25,000 of the shares have been bought on Nasdaq at an average price of USD 7.19 per share. Following the completion of the above transactions, GOGL owns a total of 952,428 of own shares, corresponding to 0.47% of the Company’s share capital. An overview of all transactions made under the buy-back program that have been carried out during the above-mentioned date is attached to this repor
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.6.2023 22:00:00 CEST | Press release
Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8, 2023– Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 36,006 divided into 36,006 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are